Synthesis of 2-(6-substituted quinolin-4-yl)-1-alkoxypropan-2-ol as potential antimycobacterial agents. 2023

Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
Department of Chemistry, S. P. Mandali's Sir Parashurambhau College (Affiliated to, Savitribai Phule Pune University), Tilak Road, Pune, 411030 India.

Resistance to antibiotic drugs has directed global health security to a life-threatening situation due to mycobacterial infections. In search of a new potent antimycobacterial, a series of (±) 2-(6-substituted quinolin-4-yl)-1-alkoxypropan-2-ol (8a-p) have been synthesized. The structures of the newly synthesized derivatives were characterized by spectrometric analysis. Derivatives 8a-p were evaluated for antitubercular activity against Mycobacterium tuberculosis H37Rv (ATCC 25177), antibacterial activity against Proteus mirabilis (NCIM2388), Escherichia coli (NCIM 2065), Bacillus subtilis (NCIM2063) Staphylococcus albus (NCIM 2178) and antifungal activity against Candida albicans (NCIM 3100), Aspergillus niger (ATCC 504). Thirteen 2-(6-substituted quinolin-4-yl)-1-alkoxypropan-2-ol (8a-m) derivatives reported moderate to good antitubercular activity against M. tuberculosis H37Rv with MIC 9.2-106.4 μM. Compounds 8a and 8h showed comparable activity with respect to the standard drug pyrazinamide. The active compounds screened for cytotoxicity activity against L929 mouse fibroblast cells showed no significant cytotoxic activity. Compounds 8c, 8d, 8e, 8g, 8k, and 8o displayed good activity against S. albus. Compounds 8c and 8n showed good activity against P. mirabilis and E. coli, respectively. The potential antimycobacterial activities imposed that the 2-(6-substituted quinolin-4-yl)-1-alkoxypropan-2-ol derivatives could lead to compounds that could treat tuberculosis. The online version contains supplementary material available at 10.1007/s11696-023-02741-3.

UI MeSH Term Description Entries

Related Publications

Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
December 2013, Bioorganic & medicinal chemistry letters,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
February 2013, Bioorganic & medicinal chemistry letters,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
January 2009, Archives of pharmacal research,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
April 2011, Bioorganic & medicinal chemistry,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
June 2010, Acta crystallographica. Section E, Structure reports online,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
September 2012, Bioorganic & medicinal chemistry letters,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
November 2005, Bioorganic & medicinal chemistry letters,
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
March 2013, Molecules (Basel, Switzerland),
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
November 2012, Medicinal chemistry (Shariqah (United Arab Emirates)),
Abhijit Shinde, and Prashant P Thakare, and Yogesh Nandurkar, and Abhijit Chavan, and Abdul Latif N Shaikh, and Pravin C Mhaske
January 2013, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!